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Antagonist design through forced 
electrostatic mismatch 
The structure of an lnterleukin-4 mutant shows that an uncompensated charge 
disables the interaction between cytokine and low-affinity receptor. 
Sir - The binding of cytokines to 
their receptors is governed by typi-
cal protein-protein interactions, 
wh'ich determine the specificity and 
kinetics of the recognition process1• 
Antagonists of cytok.ines are variants 
which bind tightly to one receptor 
subunit without causing receptor 
oligomerization. Design of cytokine 
antagonists may be the most ratio-
nal way to suppress specific signal-
ling pathways. 
Interleukin 4 (IL-4) is a typical 
cytokine with a broad range of bio-
logical activities on various cell types 
of the lymphoid system (for recent 
reviews see refs 2, 3). This cytokine 
is weil characterised structurallr9 
Fig. 1 Backbanemodel (top) and solvent accessible surfaces of the binding epitope (bottom) of the averaged minimized structures 
of a, wild-type IL-4, b, Y124G and c, Y 1240. ln the backbone model, the sidechains of C3, 15, QB, G9, 111, K 12, N 15 Q 114, 
R 1 15, K 117, T11 8, R 121, Q122, X124. S 125, and C 127 are included. The solvent accessiblity was calculated using a 1.4 A radius 
rolling probe in the program GRASP. The epitope which is majorly responsible for the binding of the secend receptor subunit is 
indicated by a circle. Nitrogenatomsare drawn in blue, oxygen atoms in red. 
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Fig. 2 Electrostatic potentials of the a, IL-4 wild-type, b, Y124G and c, Y124D as calculated by numerically solving the finite 
difference linearized Poisson-Boltzmann equation using the program UHBD, version 4.0 (ref. 21). The OPLS parameter set 
(ref. 22), with the radii of hydrogen atoms set to 1.2 A, was used to assign atomic radii and partial charges. Dielectricconstants 
of 78 and 2 were assigned to the solvent and the solute respectively. The solvent-sotute dielectric boundary smoothing was 
implemented21, the ionic strength of the solvent was set to 145 mM and to folfow a Boltzmann distribution at 300K. 
A 2 A exclusion layer was used. A grid with a 1 A spacing was taken for the calculations. The grids were contoured at +1- 0.3 
Kcal mol·'. The side chains of the residue Tyr 124 a and Asp 124 c are included as space filling models (carbon atoms are drawn 
in green, oxygen atoms in red). 
and appears to be involved in the spe-
cific expression of lgE low-affinity 
receptor (FcERII, CD23). It also acts 
as an isotype switching factor medi-
ating the switch from IgM to IgG 1 
and IgE expression. Its involvement 
in allergic diseases makes IL-4 an im-
portant target for drug design. Al-
though a homodimeric IL-4/IL-4R 
complex has been modelled by sev-
eral groups10•11 , it has recently been 
proposed that the y-chain of the IL-
2 receptor is involved in the IL-4 sys-
tem 12-u. IL-4, IL-2 and human 
growth hormone (hGH) were the 
first cytokines for which point mu-
tants with antagonistic proflies were 
reported' 4- 16• These antagonists 
function differently. In the case of 
hGH, a steric block to the binding 
of the second receptor unit was in-
troduced by the substitution of gly-
cine to a tryptophan residue 16• In 
contrast, the IL-4 variant Yl24D is 
an efficient antagonist although the 
side chain of tyrosine, is replaced by 
a sterically less demanding one, as-
partic acid. The variantY124G shows 
a strongly reduced agonism; only 
20% of the activity remains. Similar 
observations have been rnade for IL-
2 (ref. 15). Such a large activity 
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change due to the substitution of one 
residue seems paradoxical in view of 
the }arge binding area between the 
hormone and the receptor subunit17• 
Other studies have suggested that the 
activity changes are due to large 
structural changes in the mutant 
protein6•10•11 • 
To address this question, we have 
derived the structures of the mutants 
Y124G and Y124D in so)ution by 
nuclear magnetic resonance spec-
troscopy. The structures were calcu-
lated using a hybrid distance geom-
etry-simulated annealing protocol 18 
and the program Xplor19• The mutant 
structures were calculated on the basis 
of998 NOEs (Yl24D) and 973 NOEs 
(Yl24G) (see Table Ia); the data were 
taken from NOESY spectra with mix-
ing times of20, 40 and 80 ms (ref. 9). 
The structures of the mutants 
Yl24G and Yl24D are very similar 
to those of the wild-type protein. The 
root-mean-square deviation be-
tween the X-ray structure, 1rcb, and 
our mutant structures is 1.36 A 
(Yl24G) and 1.53 A (Y124D) (Ca, 
N, C' of residues 5-125). Very simi-
lar values are observed for the other 
NMR structures'~ (see Table J b). 
The r.m.s.d. for residues 5-19 and 
109-125 (helix A and D) between 
lrcb and Yl24G is 0.88 A and for 
Y124D is 0.96 A. This shows that the 
effect of the mutations and hence the 
reason for the antagonistic activity 
is not in the unfolding of helices D 
and A (refs 6,10,11). The decreasing 
agonism must therefore be attributed 
to changes in the electrostatic poten-
tial or to changes in the hydropho-
bicity of the surface. A detailed in-
spection of the mutation site in the 
wild type and the variants shows that 
the epitope's structure remains in-
tact. The Ö-carbon of the aspartic 
acid residue in the mutan t Y\24 D su-
perimposes with they-carbon of the 
tyrosine ring in the wild-type pro-
tein. The side chain of Arg 121 is or-
dered up to the Ö-carbon in all three 
structures, although the position of 
the guanidinium group cannot be 
determined. The sidechain ofSer 125 
is in a very similar position in all three 
structures. The position ofthe amidc 
group of the side chain of Glu 8 var-
ies, its whole side chain is protrud-
ing straight into solution. 
A detailed comparison of thc 
binding epitope surface between the 
IL-4 wild-type and the Y124G and 
Y 1240 variants is shown in Fig. 1. 
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The importance of the hydrophobic 
area made up by the aromatic ring 
of Tyr Ii4 is supported by the find-
ing that a phenylalanine or a histi-
dine in place of the tyrosine shows 
the same activity as the wild-type1\ 
but the Gly mutant (and Yl24N or 
Yl24K) shows an activity of only 
20% in the T-cell proliferation test. 
This indicates that this loss of activ-
ity can be directly attributed to the 
loss of appro:ximately 60 A2 ofhydro-
phobic surface (Fig. lb). Estimating 
a binding energy of 20 cal A-2 for hy-
drophobic interactions20, 'the dele-
tion' of a hydrophobic surface of this 
size should result in a reduction of 
binding energy of about 1 kcal 
mol-1, in agreement with results ob-
tained by Cunningham and Wells'. 
The activity decreases further with 
the introduction of a negatively 
charged side chain in the antagonist 
Y124D (Fig. lc). In this case, the 
binding surface is not dramatically 
reduced, but now a strongly nega-
tively charged group appears in place 
of the tyrosine ring. 
Calculations of the electrostatic 
properties at the mutation site show 
that the wild-type protein exposes a 
slightlypositive potential in this area, 
which is changed to a negative charge 
through the carboxyl group of the 
aspartate side chain (Fig. 2a-c). Al-
though the electrostatic interactions 
may contribute less to the binding 
strength than hydrophobic interac-
tions1, the repulsive forces intro-
duced by a mismatch of the electro-
static potentials must be large and 
cannot be compensated for by other 
interactions involved in the binding 
of the second receptor subunit, and 
hence reduce the activity further24• 
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Table 1a 
Type of NOE 
intra-residue 
sequential 
medium-range 
Ieng-range 
total 
wild-type IL-4 
259 
391 
172 
224 
1046 
medium-range NOE: (i,j). i+2 s j s i+4 
Ieng-range NOE: (i,j), j ~ i+S 
Y124G 
273 
347 
156 
197 
973 
Y124D 
272 
363 
158 
205 
998 
Table 1b 
atoms used in alignment lrcb- IL-4 lrcb- Y124G lrcb- Y124D 
5-125 backbone 1.58 1.36 1.53 
heavy atoms 2.46 2.32 2.37 
5-19 and 109-125, backbone 0.74 0.88 0.96 
heavy atoms 1.80 1.93 1.91 
109-125 backbone 0.50 0.73 0.53 
heavy atoms 1.78 1.97 1.78 
5-19 and 109-125, bb plus 
heavy atoms of core- 1.21 1.21 1.29 
forming residues• 
backbone atoms = Ccx, N and C' 
*Heavy atoms of residue types isoleucine, leucine, phenylalanine, tyrosine and 
methionine were used. 
Zn summary, this work shows that 
an effective four helix bundle 
cytokine antagonist can be designed 
by the removal of a larger hydropho-
bic area and the introduction of an 
electrostatic mismatch with the 
receptor. 
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